■作为一种流行的抗糖尿病药物,teneligliptin已经使用了10多年,但其疗效和安全性很少得到系统评价.因此,本研究进行了贝叶斯网络荟萃分析,以评价泰利列汀在2型糖尿病(T2DM)患者中的疗效和安全性.
■我们系统地搜索了PubMed,WebofScience,Embase,Cochrane中央控制试验登记册,和ClinicalTrials.gov.该研究包括在T2DM患者中比较teneligliptin与安慰剂或主动比较至少12周的随机对照试验(RCT)。采用R4.2.3和Stata17.0软件进行数据分析。每个结果都以平均差(MD)或比值比(OR)以及95%置信区间(CI)和累积排名曲线值(SUCRA)下的表面表示。
■本研究共纳入18项RCT,3,290名T2DM参与者。一般来说,与安慰剂相比,西格列汀,维格列汀,二甲双胍,和溴隐亭,20毫克泰利格汀在降低HbA1c方面表现出更好的疗效(MD[95%CI],-0.78[-0.86至-0.70],-0.08[-0.36至0.19],-0.04[-0.72至0.60],-0.12[-0.65至0.42],和-0.50[-0.74至-0.26],分别)和空腹血糖(FPG)(MD[95%CI],-18.02[-20.64至-15.13],1.17[-9.39至11.70],-8.06[-30.95至14.35],-2.75[-18.89至13.01],和-34.23[-45.93至-22.96],分别),和40毫克的teneligliptin也显示出更好的疗效在降低HbA1c(MD[95%CI],-0.84[-1.03至-0.65],-0.15[-0.49至0.19],-0.10[-0.81至0.57],-0.18[-0.76至0.39],和-0.56[-0.88至-0.26],分别)和FPG(MD[95%CI],-20.40[-26.07至-14.57],-1.20[-13.21至10.38],-10.43[-34.16至12.65],-5.13[-22.21至11.66],和-36.61[-49.33至-24.01],分别)。与安慰剂相比,20mg的泰利格汀在低血糖和胃肠道不良事件的发生率方面没有显着差异(OR[95%CI],1.30[0.70至2.19]和1.48[0.78至2.98],分别),和40mg的teneligliptin在低血糖发生率方面没有显着差异(OR[95%CI],2.63[0.46to8.10]).一般来说,随着剂量从5mg增加到40mg,teneligliptin的抗糖尿病作用和低血糖风险逐渐增加。与20毫克的teneligliptin相比,40毫克的teneligliptin显示出较好的疗效和不差的安全性,这被认为是降低HbA1c的最佳选择,FPG,和2hPPG,达到HbA1c<7%的患者比例增加(SUCRA,85.51%,84.24%,79.06%,85.81%,分别)在所有纳入的干预措施中。
■与西格列汀相比,维格列汀,二甲双胍,溴隐亭,和安慰剂,Teneligliptin在治疗T2DM方面显示出良好的疗效和可接受的安全性。每天20毫克或40毫克是teneligliptin的最佳剂量方案。本研究结果将为泰利格汀的合理使用和2型糖尿病的临床用药决策提供重要的循证依据。
As a popular antidiabetic drug, teneligliptin has been used for over 10 years, but its efficacy and safety have rarely been systematically evaluated. Therefore, a Bayesian network meta-analysis was conducted to evaluate the efficacy and safety of teneligliptin in patients with type 2 diabetes mellitus (T2DM).
We systematically searched PubMed, Web of Science, Embase, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov. Randomized controlled trials (RCTs) comparing teneligliptin with placebo or active comparators in T2DM patients for at least 12 weeks were included in the study. Data analysis was performed using R 4.2.3 and Stata 17.0 software. Each outcome was presented as a mean difference (MD) or an odds ratio (OR) along with 95% confidence interval (CI) and the surface under the cumulative ranking curve value (SUCRA).
A total of 18 RCTs with 3,290 participants with T2DM were included in this study. Generally, compared to placebo, sitagliptin, vildagliptin, metformin, and
bromocriptine, 20 mg of teneligliptin showed better efficacy in reducing HbA1c (MD [95% CI], -0.78 [-0.86 to -0.70], -0.08 [-0.36 to 0.19], -0.04 [-0.72 to 0.60], -0.12 [-0.65 to 0.42], and -0.50 [-0.74 to -0.26], respectively) and fasting plasma glucose (FPG) (MD [95% CI], -18.02 [-20.64 to -15.13], 1.17 [-9.39 to 11.70], -8.06 [-30.95 to 14.35], -2.75 [-18.89 to 13.01], and -34.23 [-45.93 to -22.96], respectively), and 40 mg of teneligliptin also showed better efficacy in reducing HbA1c (MD [95% CI], -0.84 [-1.03 to -0.65], -0.15 [-0.49 to 0.19], -0.10 [-0.81 to 0.57], -0.18 [-0.76 to 0.39], and -0.56 [-0.88 to -0.26], respectively) and FPG (MD [95% CI], -20.40 [-26.07 to -14.57], -1.20 [-13.21 to 10.38], -10.43 [-34.16 to 12.65], -5.13 [-22.21 to 11.66], and -36.61 [-49.33 to -24.01], respectively). Compared to placebo, 20 mg of teneligliptin showed no significant difference in incidences of hypoglycemia and gastrointestinal adverse events (OR [95% CI], 1.30 [0.70 to 2.19] and 1.48 [0.78 to 2.98], respectively), and 40 mg of teneligliptin showed no significant difference in incidence of hypoglycemia (OR [95% CI], 2.63 [0.46 to 8.10]). Generally, antidiabetic effect and hypoglycemia risk of teneligliptin gradually increased as its dose increased from 5 mg to 40 mg. Compared to 20 mg of teneligliptin, 40 mg of teneligliptin showed superior efficacy and no-inferior safety, which was considered as the best option in reducing HbA1c, FPG, and 2h PPG and increasing proportion of the patients achieving HbA1c < 7% (SUCRA, 85.51%, 84.24%, 79.06%, and 85.81%, respectively) among all the included interventions.
Compared to sitagliptin, vildagliptin, metformin,
bromocriptine, and placebo, teneligliptin displayed favorable efficacy and acceptable safety in treating T2DM. Twenty milligrams or 40 mg per day was the optimal dosage regimen of teneligliptin. The results of this study will provide important evidence-based basis for rational use of teneligliptin and clinical decision-making of T2DM medication.